Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.55 |
| ▸ | CDK9 | P50750 | 3/20 | 0.55 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.53 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.53 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244521 | 0.98 | CYP1A2 (0.57) | ADORA3CYP1A2CYP2C9CLK4CCNT1 | |
| SCHEMBL1242251 | 0.93 | PIP4K2A (0.61) | ADORA3CYP1A2CYP2C9CLK4CCNT1 | |
| SCHEMBL4114071 | 0.91 | CCNT1 (0.67) | CCNT1CDK9PIP4K2APIP4K2BPOLB | |
| SCHEMBL4097416 | 0.90 | POLB (0.63) | CYP1A2CYP2C9CLK4CCNT1CDK9 | |
| SCHEMBL4114258 | 0.90 | ABL1 (0.51) | ADORA3CYP1A2CYP2C9CLK4CCNT1 | |
| SCHEMBL1243593 | 0.89 | ABL1 (0.58) | CYP2C9CCNT1CDK9POLBLMNA | |
| SCHEMBL5752060 | 0.89 | CCNT1 (0.67) | CCNT1CDK9PIP4K2APIP4K2BMAPT | |
| SCHEMBL1244551 | 0.88 | CCNT1 (0.50) | ADORA3CYP1A2CYP2C9CLK4CCNT1 | |
| SCHEMBL1244724 | 0.87 | RAB9A (0.56) | ADORA3CYP1A2CYP2C9CLK4LMNA | |
| SCHEMBL4666194 | 0.86 | TP53 (0.61) | CYP1A2CYP2C9CLK4CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | claimed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | claimed |
| US-8084457-B2 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | LEAD DISCOVERY CENTER GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20090221581-A1 | Methods of treating pain | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1763526-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Altana Pharma AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | DAPK1, DUSP4, MARK4 | ADORA3 890/4885CYP1A2 4187/4885CYP2C9 3672/4885 |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | ADORA3 1415/4885CYP1A2 2241/4885CYP2C9 2199/4885 |
| US-20090221581-A1 | Methods of treating pain | CDK5, CAMKK2, CDK3 | ADORA3 1865/4885CYP1A2 4521/4885CYP2C9 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.